For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday. The company released patient updates on ...

Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...

For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab ...

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort ...

In some with grade 3 brain cancer, adding PCV chemotherapy regimen to radiation showed better survival outcomes than another ...

Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.

Patients with limited-stage SCLC were randomly assigned to receive durvalumab with or without tremelimumab or placebo as ...

Short-course induction chemotherapy prior to chemoradiotherapy should be considered a standard of care, according to ...